Neuropathic pain in the community: More under-treated than refractory?

Pain

Volumn 154, Issue 5, 2013, Pages 690-699

  Torrance, Nicola ^a   Ferguson, Janice A ^a   Afolabi, Ebenezer ^b   Bennett, Michael I ^c   Serpell, Michael G ^d   Dunn, Kate M ^e   Smith, Blair H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

Chronic pain; Epidemiology; Neuropathic pain; Refractory; S LANSS

Indexed keywords

ANALGESIC AGENT;

ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DELPHI STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN SELF EFFICACY QUESTIONNAIRE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REFRACTORY NEUROPATHIC PAIN; SELF ADMINISTERED LEEDS ASSESSMENT OF NEUROPATHIC SIGNS AND SYMPTOMS; SELF CONCEPT; SHORT FORM 12; UNITED KINGDOM;

EID: 84878019309     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2012.12.022     Document Type: Article

References (53)

1. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T. European federation of neurological societies. EFNS guidelines on the pharmacological treatment of neuropathic pain. Eur J Neurol 2010 revision;2010:e1113-88.
2. Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. PAIN 2011;152:2836-43.
3. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain be more or less neuropathic Comparison of symptom assessment tools with ratings of certainty by clinicians. PAIN 2006;122:289-94.
4. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005;6:149-58.
5. Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, Rabaud C, Rogeaux O, Strady C. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. PAIN 2012;153:342-9.
6. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. PAIN 2008;136:380-7.
7. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333.
8. British National Formulary. BMA. Royal Pharmaceutical Society, London: BMJ Group and Pharmaceutical Press; 2010.
9. Carmona L, Ballina J, Gabriel R, Laffon A. EPISER study group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001;60:1040-5.
10. Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice AS. Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs. Eur J Pain 2008;12:731-41.
11. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. PAIN 2010;149:338-44.
12. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations PAIN 2012;153:869-75.
13. Elliott AM, Smith BH, Hannaford PC, Smith WC, Chambers WA. The course of chronic pain in the community: results of a 4-year follow-up study. PAIN 2002;99:299-307.
14. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet 1999;354:1248-52.
15. EuroQoL Group. EuroQoL-A new facility for the measurement of healthrelated quality of life. Health Policy 1990;16:199-208.
16. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. PAIN 2010;150:573-81.
17. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007;17:643-53.
18. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie D. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007;11:652-64.
19. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract 2008;9:26.
20. Hansson PT, Attal N, Baron R, Cruccu G. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain 2009;13:439-40.
21. International Association for the Study of Pain. Classification of chronic pain. Pain Suppl 1986;3:S1-S225.
22. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med 2011;28:395-413.
23. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. PAIN 2011;152:2204-5.
24. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41.
25. Korkeila K, Suominen S, Ahvenainen J, Ojanlatva A, Rautava P, Helenius H, Koskenvuo M. Non-response and related factors in a nation-wide health survey. Eur J Epidemiol 2001;17:991-9.
26. Langley PC. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011;27:463-80.
27. McAteer A, Elliott AM, Hannaford PC. Ascertaining the size of the symptom iceberg in a UK-wide community-based survey. Br J Gen Pract 2011;61:e1-e11.
28. Miles CL, Pincus T, Carnes D, Taylor SJ, Underwood M. Measuring pain selfefficacy. Clin J Pain 2011;27:461-70.
29. National Institute for Health Research (NIHR). NIHR Clinical Research Network, http://www.crncc.nihr.ac.uk/about-us/processes/portfolio; [accessed 18.10.2012].
30. NHS. The Information Centre for health and social care. Attribution dataset GP registered populations 2010-2011, http://www.ic.nhs.uk/statistics- anddata-collections/population-and-geography/gp-registered-populations/ attribution-dataset-gp-registered-populations-2010; [accessed 03.04.12].
31. NICE Clinical Guideline 96: pharmacological management of neuropathic pain in non-specialist settings. London: National Institute of Health and Clinical Excellence, http://www.nice.org.uk/nicemedia/live/12948/47949/47949. pdf; http://guidance.nice.org.uk/CG96 2010; [accessed 18.10.2012].
32. Nicholas MK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain 2007;11:153-63.
33. Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid psychosocial factors are associated with poor health-related quality of life in subjects with new onset of chronic widespread pain -results from the EPIFUND study. PAIN 2009;141:119-26.
34. Niv D, Devor M. Refractory neuropathic pain: the nature and extent of the problem. Pain Pract 2006;6:3-9.
35. Scottish Medicines Consortium. Scottish Medicines Consortium advice to NHS Scotland. Briefing note. Pregabalin (Lyrica). NHS Scotland; 2009. Report No. 18. http://www.scottishmedicines.org.uk/files/briefing-notes/2009/ Briefing-note-smc-May09.pdf.
36. Poliakov I, Toth C. The impact of pain in patients with polyneuropathy. Eur J Pain 2011;15:1015-22.
37. Scottishz School of Primary Care. Scottish Primary Care Research Network, http://www.sspc.ac.uk/spcrn/; [accessed 18.10.2012].
38. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K. The impact of chronic pain in the community. Fam Pract 2001;18:292-9.
39. Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, Chambers WA, Smith WC. The chronic pain grade questionnaire: validation and reliability in postal research. PAIN 1997;71:141-7.
40. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012;16:191-8.
41. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-9.
42. Smith BH, Torrance N, Ferguson JA, Bennett MI, Serpell MG, Dunn KM. Towards a definition of refractory neuropathic pain for epidemiological research. An international Delphi survey of experts. BMC Neurol 2012;12:29.
43. Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-8.
44. Stoate HG. Can health screening damage your health J R Coll Gen Pract 1989;39:193-5.
45. Taylor RS. Epidemiology of refractory neuropathic pain. Pain Pract 2006;6:22-6.
46. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9.
47. Torrance N, Smith BH, Watson MC, Bennett MI. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam Pract 2007;24:481-5.
48. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
49. Turk DC, Audette J, Levy RM, Mackey SC, Stanos S. Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc 2010;85:S42-50.
50. Van Loon AJ, Tijhuis M, Picavet HS, Surtees PG, Ormel J. Survey non-response in The Netherlands : effects on prevalence estimates and associations. Ann Epidemiol 2003;13:105-10.
51. Von Korff M. Epidemiologic and survey methods: chronic pain assessment. In: Turk DC, Melzack R, editors. Handbook of pain assessment. New York: Guilford Press; 2001. p. 603-18.
52. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. PAIN 1992;50:133-49.
53. Ware Jr J, Kosinski M, Kellerz SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.